Catalyst Pharmaceuticals (CPRX) Return on Capital Employed (2011 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Return on Capital Employed came in at 26.94% in Q1 2026, down 316.0% YoY from 12.47% in Q1 2025, and down 2.73% on a QoQ basis from 27.7% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 16 years of Return on Capital Employed data on file, last reported at 26.94% in Q1 2026.
- Quarterly Return on Capital Employed fell 316.0% year-over-year to 26.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.94% (down 316.0% YoY) and the FY2025 annual result came in at 31.04%, down 509.0% from the prior year.
- Return on Capital Employed slipped to 26.94% in Q1 2026, from 27.7% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.05% in Q2 2023 to a low of 14.7% in Q2 2024.
- A 5-year average of 27.81% and a median of 28.24% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 2235 bps — and 2025, when it jumped 1472 bps.
- Tracing CPRX's Return on Capital Employed over 5 years: stood at 34.31% in 2022, then slumped by 31 bps to 23.75% in 2023, then advanced by 19 bps to 28.24% in 2024, then decreased by 2 bps to 27.7% in 2025, then declined by 3 bps to 26.94% in 2026.
- The last three Return on Capital Employed figures came in at 26.94% (Q1 2026), 27.7% (Q4 2025), and 29.31% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 26.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.94% |
| Dec 31, 2025 | 27.70% |
| Sep 30, 2025 | 29.31% |
| Jun 30, 2025 | 29.42% |
| Mar 31, 2025 | 30.11% |
| Dec 31, 2024 | 28.24% |
| Sep 30, 2024 | 27.45% |
| Jun 30, 2024 | 14.70% |
| Mar 31, 2024 | 16.36% |
| Dec 31, 2023 | 23.75% |
| Sep 30, 2023 | 20.48% |
| Jun 30, 2023 | 37.05% |
| Mar 31, 2023 | 35.88% |
| Dec 31, 2022 | 34.31% |
| Sep 30, 2022 | 32.79% |
| Jun 30, 2022 | 30.97% |
| Mar 31, 2022 | 27.32% |
| Dec 31, 2021 | 25.75% |
| Sep 30, 2021 | 24.68% |
| Jun 30, 2021 | 24.57% |